Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16
Name of entity QRxPharma Limited ABN Quarter ended ("current quarter") 16 102 254 151 30/09/2017Consolidated statement of cash flows | Current quarter $A'000 | Year to date (3 months) $A'000 |
1.0 Cash flows from operating activities | (110) | (110) |
1.1 Receipts from customers | ||
1.2 Payments for | ||
(a) research and development | ||
(b) product manufacturing and operating costs | ||
(c) advertising and marketing | ||
(d) leased assets | ||
(e) staff costs | ||
(f) administration and corporate costs | ||
1.3 Dividends received (see note 3) | ||
1.4 Interest received | 1 | 1 |
1.5 Interest and other costs of finance paid | ||
1.6 Income taxes paid | ||
1.7 Government grants and tax incentives | ||
1.8 Other (provide details if material) | ||
1.9 Net cash from / (used in) operating activities | (109) | (109) |
Payments to acquire:
property, plant and equipment
businesses (see item 10)
investments
intellectual property
other non-current assets
Proceeds from disposal of:
property, plant and equipment
businesses (see item 10)
investments
intellectual property
other non-current assets
2.6 Net cash from / (used in) investing activities | |
- | - |
3.0 Cash flows from financing activities
3.10 Net cash from / (used in) financing activities | |
- | - |
4.0 Net increase / (decrease) in cash and cash equivalents for the period
4.6 Cash and cash equivalents at end of quarter | 641 (109) - - (1) | 641 (109) - - (1) |
531 | 531 |
Reconciliation of cash and cash equivalents 5.0 at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | Current quarter $A'000 | Previous quarter $A'000 |
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above) | 531 | 641 |
531 | 641 |
Aggregate amount of payments to these parties included in item 1.2
34
Aggregate amount of cash flow from loans to these parties included in item 2.3
Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2
Current quarter $A'000 |
Aggregate amount of payments to these parties included in item 1.2
Aggregate amount of cash flow from loans to these parties included in item 2.3
Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2
Total facility amount at quarter end | Amount drawn at quarter end |
$A'000 | $A'000 |
8.0 Add notes as necessary for an understanding of the position
Loan facilities
Credit standby arrangements
Other (please specify)
Include below a description of each facility above, including the lender, interest rate and whether it is
secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.
9.0 Estimated cash outflows for next quarter | $A'000 |
9.1 Research and development | - |
9.2 Product manufacturing and operating costs | - |
9.3 Advertising and marketing | - |
9.4 Leased assets | - |
9.5 Staff costs | - |
9.6 Administration and corporate costs | 124 |
9.7 Other (provide details if material) | - |
9.8 Total estimated cash outflows | 124 |
10.0 | Acquisitions and disposals of business | Acquisitions | Disposals |
entities | |||
(items 2.1(b) and 2.2(b) above) | |||
10.1 | Name of entity | ||
10.2 | Place of incorporation or registration | ||
10.3 | Consideration for acquisition or disposal | ||
10.4 | Total net assets | ||
10.5 | Nature of business |
This statement has been prepared in accordance with accounting standards and policies which comply with Listing
1 Rule 19.11A.
2 This statement gives a true and fair view of the matters disclosed.
Sign here: Date: 17/10/2017
Company secretary
Print name: Cameron Jones
Notes1
2
3
The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
QRxpharma Ltd. published this content on 17 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 17 October 2017 03:34:03 UTC.
Original documenthttp://www.qrxpharma.com/irm/PDF/1556_0/Appendix4CQuarterEnded30September2017
Public permalinkhttp://www.publicnow.com/view/2FA286CB60A7C9B425240BDE97BE311E9985706C